Oncology
Oncology
Taking Cancer on
At Boehringer Ingelheim, we believe this can be the generation that redefines many cancers as curable diseases. We want to be part of this transformation.
Optimising outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?
Document ID: PC-TH-100289
01/12/2018
Author: Dr Nicolas Girard
Treatment sequences in EGFR-mutant NSCLC after 1st-line EGFR TKI
123,000
Views
100k 340
PC-TH-100291
Production date: Dec 2018
Production date: Dec 2018